ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting.  Sign up here.

CHICAGO — It’s only Day 2, but the ASCO meeting is already in full force. That means hordes of oncologists filling the halls, reams of data streaming through the meeting, and incredibly long lines for even the worst food. And STAT reporters Angus Chen, Adam Feuerstein, and Matthew Herper are in the thick of it – on the heels of STAT’s own in-person event here, which was standing room only and came with its own share of thrills, chills, and not a little bit of audience laughter. More on that in a bit.

Here’s a rundown of some of the big news from the first 24 hours of the meeting which, due to some weird kind of relativistic time dilation, represents about a week for our intrepid reporters.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In